X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with Metastatic Microsatellite stable colorectal cancer.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2024
Details:
Under the agreement, Bristol licensed BMS-986442 (AGEN1777), a dual TIGIT and CD96 antagonist with an enhanced Fc region to improve tumor-reactive T cell responses, from Agenus and currently dosed first patient in the phase 2 of the ongoing clinical trial.
Lead Product(s): AGEN1777,Docetaxel,Nivolumab
Therapeutic Area: Oncology Product Name: BMS-986442
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $1,560.0 million Upfront Cash: $200.0 million
Deal Type: Licensing Agreement December 11, 2023
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds ctla-4 and has demonstrated activity in cancer patients. it has received fast track designation for colorectal cancer.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds CTLA-4. The antibody was designed to enhance FcγR effector functions while avoiding complement-related toxicities and has demonstrated activity in cancer patients.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
AGEN1181 (botensilimab) is a next-generation, Fc-enhanced, immunoglobulin G1 (IgG1) antibody designed to block CTLA-4 (cytotoxic T-lymphocyte associated antigen 4) from interacting with its ligands CD80 and CD86.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
AGEN1181 is an Fc-enhanced anti–CTLA-4 monoclonal antibody. The botensilimab/balstilimab combination produced superior responses and strong durability relative to what has been reported in separate trials for standard of care and other combinations currently in development.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
AGEN1181 (botensilimab) is an Fc-enhanced anti–CTLA-4 monoclonal antibody. Botensilimab was well tolerated, with no new immune-mediated safety signals outside of those observed in the class.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
